alirocumab vs pravastatin
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of alirocumab and pravastatin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Praluent
Pravachol
Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.
Pravastatin is a drug that lowers cholesterol. It belongs to a class of drugs called statins.
Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.
Pravastatin helps lower bad cholesterol and fats (like triglycerides) in your blood, while raising good cholesterol. It can help prevent heart attacks, strokes, and the need for procedures to open blocked arteries. It is used along with a healthy diet to treat high cholesterol and other fat disorders in adults and children 8 years and older.
Praluent is a PCSK9 inhibitor. It works by blocking a protein in your body called PCSK9. Blocking this protein helps your body remove LDL cholesterol from your blood.
Pravastatin works by blocking a substance your body needs to make cholesterol. This helps to lower the amount of cholesterol in your blood. Lowering cholesterol helps to prevent heart disease and stroke.
- • Injection site reactions (redness, itching, swelling, pain)
- • Flu
- • Muscle pain
- • Diarrhea
- • Muscle pain
- • Nausea
- • Vomiting
- • Diarrhea
- • Headache
- Myalgia 1,655
- Product Dose Omission 1,364
- Injection Site Pain 1,278
- Muscle Spasms 1,162
- Arthralgia 1,053
- Fatigue 1,262
- Diarrhoea 1,095
- Nausea 954
- Dyspnoea 927
- Headache 842
Serious allergic reactions have happened with Praluent, sometimes requiring hospitalization. If you have signs of a serious allergic reaction, stop using Praluent and get medical help right away.
Pravastatin can sometimes cause muscle problems, including muscle pain, tenderness, or weakness. In rare cases, this can lead to serious muscle damage called rhabdomyolysis, which can cause kidney failure. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. This medicine can also cause liver problems. Your doctor should do blood tests to check your liver before you start taking pravastatin and if you have any symptoms of liver problems.
There is not enough information about Praluent use during pregnancy to know if it is safe. If you are pregnant or plan to become pregnant, talk to your doctor before using Praluent.
You should not take pravastatin if you are pregnant. It can harm your unborn baby. If you become pregnant while taking pravastatin, stop taking it right away and tell your doctor.
Also Compare, Nearby Drugs
Compare alirocumab with
Compare pravastatin with
How to Read This alirocumab vs pravastatin Comparison
alirocumab is classified in the PCSK9 Inhibitor drug class, while pravastatin sits within the HMG-CoA Reductase Inhibitor (Statin) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alirocumab has 6,512 submissions while pravastatin has 5,080. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for alirocumab or pravastatin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.